Patrick Daly

Cancer Nursing Today nonprod

Pulmonary chronic graft-versus-host disease (cGVHD), also called bronchiolitis obliterans syndrome (BOS), is one of the most dangerous complications of allogeneic hematopoietic stem cell transplantation (HSCT) and, according to a study published in BMC Pulmonary Medicine, is often diagnosed after lung dysfunction has become irreversible.Researchers examined whether a pulmonary function test (PFT) prior to HSCT was able to identify patients who may be at risk and found the forced expiratory volume during 1 second to forced vital capacity (FEV1/FVC) and peak expiratory flow to predictive value (PEF/pred) ratios could be potential predictors for pulmonary cGVHD and even transplant outcomes.<a href="https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-022-02278-3" target="_blank" rel="noopener">The study</a> included 923 allogeneic HSCT recipients from a single center, of which 15 later developed pulmonary cGVHD. Investigators used Kaplan-Meier and Cox regression models to assess 3-year progression-free survival and overall survival (OS).The 3-year cumulative incidence of pulmonary cGVHD was 2.04% (95% CI, 1.00-3.08), according to the report. Based on receiver operating characteristic curve analysis, researchers found a higher FEV1/FVC ratio was associated with a lower incidence of pulmonary cGVHD (0.91%; 95% CI, 0.01-1.81 vs 3.61%; 95% CI, 1.30-5.92; P&lt;.01). Likewise, a higher ratio of PEF/pred was correlated with a lower incidence of cGVHD (0.72%; 95% CI, 0-1.54 vs 3.74%; 95% CI, 1.47-6.01; P&lt;.01).Multivariate analysis established that FEV1/FVC (hazard ratio [HR], 3.383; P=.047) and PEF/pred (HR, 4.426; P=.027) were independent predictive variables for the onset of BOS. Higher FEV1/FVC and PEF/pred levels were associated with significantly decreased 3-year nonrelapse mortality. Of note, 3-year OS was superior in patients with higher PEF/pred (78.17%; 95% CI, 74.50-81.84 vs 71.14%; 95% CI, 66.08-76.20; P=.01), though patients with higher FEV1/FVC did not show the same difference.&ldquo;PFT is a routinely employed detection before HSCT, which may potentially predict the risk of pulmonary cGVHD and even transplant outcomes, according to our data,&rdquo; the authors concluded.Read More: <a href="https://cancernursingtoday.com/post/vitamin-d-deficiency-impacts-graft-versus-host-disease-outcomes">Vitamin D Deficiency Impacts Graft-Versus-Host Disease Outcomes</a>

Pulmonary Function Test to Predict Pulmonary cGVHD

GVHD

FEV1/FVC and PEF/pred could identify patients with higher risk for pulmonary chronic graft-versus-host disease before HSCT.

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe